Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.7400
- TODAY'S CHANGE (%)-0.1000 (-2.6042%)
- Bid / Lots3.5000/ 1
- Ask / Lots4.0000/ 10
- Open / Previous Close3.9400 / 3.8400
- Day Range
- 52 Week Range
- Volume347,866
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 16740 | 3.995 |
| 09:34 ET | 8860 | 3.97 |
| 09:36 ET | 1650 | 4.01 |
| 09:38 ET | 2518 | 4 |
| 09:39 ET | 1115 | 3.9881 |
| 09:41 ET | 868 | 4.01 |
| 09:43 ET | 2800 | 4.01 |
| 09:45 ET | 1200 | 4 |
| 09:48 ET | 500 | 4.02 |
| 09:50 ET | 1150 | 4.03 |
| 09:52 ET | 600 | 4.02 |
| 09:54 ET | 1288 | 4.02 |
| 09:56 ET | 500 | 4.02 |
| 09:57 ET | 1016 | 4.03 |
| 09:59 ET | 350 | 3.9916 |
| 10:01 ET | 100 | 3.99 |
| 10:08 ET | 1907 | 3.9412 |
| 10:14 ET | 895 | 3.91 |
| 10:17 ET | 235 | 3.92 |
| 10:21 ET | 515 | 3.8993 |
| 10:24 ET | 546 | 3.91 |
| 10:26 ET | 750 | 3.91 |
| 10:30 ET | 300 | 3.89 |
| 10:32 ET | 125 | 3.9015 |
| 10:33 ET | 100 | 3.91 |
| 10:35 ET | 258 | 3.903 |
| 10:39 ET | 100 | 3.91 |
| 10:42 ET | 100 | 3.9 |
| 10:44 ET | 400 | 3.915 |
| 10:46 ET | 100 | 3.92 |
| 10:48 ET | 200 | 3.92 |
| 10:53 ET | 599 | 3.93 |
| 11:00 ET | 1267 | 3.93 |
| 11:04 ET | 100 | 3.92 |
| 11:09 ET | 100 | 3.92 |
| 11:11 ET | 200 | 3.93 |
| 11:15 ET | 900 | 3.94 |
| 11:18 ET | 200 | 3.92 |
| 11:20 ET | 300 | 3.89 |
| 11:22 ET | 21907 | 3.9484 |
| 11:24 ET | 1572 | 3.92 |
| 11:26 ET | 100 | 3.92 |
| 11:27 ET | 200 | 3.92 |
| 11:29 ET | 600 | 3.93 |
| 11:31 ET | 100 | 3.93 |
| 11:33 ET | 200 | 3.94 |
| 11:36 ET | 31827 | 3.96 |
| 11:40 ET | 500 | 3.94 |
| 11:45 ET | 200 | 3.93 |
| 11:49 ET | 353 | 3.92 |
| 11:51 ET | 400 | 3.9 |
| 11:54 ET | 1222 | 3.91 |
| 11:56 ET | 700 | 3.92 |
| 11:58 ET | 500 | 3.915 |
| 12:02 ET | 525 | 3.9 |
| 12:03 ET | 100 | 3.9 |
| 12:05 ET | 100 | 3.91 |
| 12:07 ET | 320 | 3.89 |
| 12:09 ET | 25496 | 3.9109 |
| 12:12 ET | 3200 | 3.9214 |
| 12:14 ET | 100 | 3.93 |
| 12:18 ET | 100 | 3.93 |
| 12:20 ET | 100 | 3.93 |
| 12:21 ET | 1000 | 3.91 |
| 12:23 ET | 200 | 3.925 |
| 12:25 ET | 1669 | 3.95 |
| 12:32 ET | 4970 | 3.89 |
| 12:34 ET | 24953 | 3.91 |
| 12:36 ET | 28153 | 3.8901 |
| 12:41 ET | 400 | 3.89 |
| 12:48 ET | 125 | 3.885 |
| 12:50 ET | 510 | 3.885 |
| 12:54 ET | 200 | 3.89 |
| 12:56 ET | 100 | 3.88 |
| 12:59 ET | 300 | 3.88 |
| 01:03 ET | 200 | 3.88 |
| 01:06 ET | 740 | 3.865 |
| 01:10 ET | 100 | 3.86 |
| 01:15 ET | 100 | 3.86 |
| 01:17 ET | 200 | 3.87 |
| 01:19 ET | 200 | 3.86 |
| 01:24 ET | 1200 | 3.84 |
| 01:26 ET | 200 | 3.85 |
| 01:28 ET | 5111 | 3.87 |
| 01:30 ET | 4129 | 3.9 |
| 01:32 ET | 260 | 3.885 |
| 01:33 ET | 200 | 3.9 |
| 01:35 ET | 300 | 3.9 |
| 01:37 ET | 300 | 3.9 |
| 01:39 ET | 2508 | 3.89 |
| 01:42 ET | 400 | 3.87 |
| 01:44 ET | 100 | 3.87 |
| 01:48 ET | 443 | 3.87 |
| 01:51 ET | 100 | 3.85 |
| 01:53 ET | 300 | 3.85 |
| 01:57 ET | 100 | 3.82 |
| 02:02 ET | 200 | 3.84 |
| 02:04 ET | 8688 | 3.81 |
| 02:06 ET | 4311 | 3.8 |
| 02:08 ET | 200 | 3.79 |
| 02:09 ET | 403 | 3.79 |
| 02:11 ET | 769 | 3.8 |
| 02:13 ET | 200 | 3.8 |
| 02:15 ET | 9312 | 3.8 |
| 02:18 ET | 500 | 3.81 |
| 02:20 ET | 200 | 3.81 |
| 02:24 ET | 832 | 3.79 |
| 02:26 ET | 300 | 3.81 |
| 02:27 ET | 3355 | 3.79 |
| 02:29 ET | 100 | 3.77 |
| 02:31 ET | 150 | 3.78 |
| 02:33 ET | 200 | 3.78 |
| 02:36 ET | 832 | 3.765 |
| 02:38 ET | 1531 | 3.78 |
| 02:40 ET | 700 | 3.775 |
| 02:42 ET | 100 | 3.775 |
| 02:44 ET | 1366 | 3.77 |
| 02:45 ET | 200 | 3.76 |
| 02:47 ET | 3097 | 3.76 |
| 02:49 ET | 1101 | 3.755 |
| 02:51 ET | 1300 | 3.755 |
| 02:54 ET | 400 | 3.76 |
| 02:56 ET | 2803 | 3.77 |
| 02:58 ET | 262 | 3.76 |
| 03:02 ET | 100 | 3.75 |
| 03:03 ET | 3300 | 3.75 |
| 03:05 ET | 2889 | 3.74 |
| 03:07 ET | 800 | 3.73 |
| 03:09 ET | 200 | 3.73 |
| 03:16 ET | 355 | 3.74 |
| 03:18 ET | 200 | 3.74 |
| 03:23 ET | 1195 | 3.725 |
| 03:25 ET | 600 | 3.74 |
| 03:27 ET | 300 | 3.735 |
| 03:30 ET | 200 | 3.74 |
| 03:32 ET | 362 | 3.7399 |
| 03:36 ET | 100 | 3.73 |
| 03:38 ET | 100 | 3.735 |
| 03:41 ET | 100 | 3.74 |
| 03:43 ET | 100 | 3.74 |
| 03:45 ET | 100 | 3.735 |
| 03:48 ET | 618 | 3.735 |
| 03:50 ET | 100 | 3.73 |
| 03:54 ET | 1324 | 3.73 |
| 03:56 ET | 5385 | 3.75 |
| 03:57 ET | 300 | 3.75 |
| 03:59 ET | 1074 | 3.74 |
Today
May 13, 2024
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy, from 7:32PM ET on Monday May 13, 2024 by Dow Jones
7:32PM ET on Monday May 13, 2024 by Dow Jones
May 2, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform, from 4:30PM ET on Thursday May 02, 2024 by Dow Jones
4:30PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 201.7M | -0.8x | --- |
Trevi Therapeutics Inc | 205.7M | -8.2x | --- |
Boundless Bio Inc | 206.4M | -4.3x | --- |
INmune Bio Inc | 207.5M | -5.9x | --- |
Elevation Oncology Inc | 194.5M | -3.6x | --- |
Atossa Therapeutics Inc | 193.0M | -6.7x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Lead Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $201.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.47 |
EPS | $-4.97 |
Book Value | $5.06 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
